Home

Haemonetics Corporation Common Stock (HAE)

71.24
+2.32 (3.37%)

Haemonetics Corporation is a global healthcare company that specializes in providing innovative blood management solutions

The company develops and manufactures a range of systems and products designed to optimize the collection, processing, and transfusion of blood and its components. Haemonetics focuses on enhancing blood safety and efficiency within healthcare settings, offering technologies that support blood donation and transfusion processes, as well as promoting the overall health of patients through effective blood management practices. Their commitment to improving patient outcomes and supporting healthcare providers makes them a key player in the field of healthcare technology.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close68.92
Open69.18
Bid66.46
Ask72.00
Day's Range68.24 - 71.51
52 Week Range65.73 - 97.97
Volume1,805,407
Market Cap3.64B
PE Ratio (TTM)29.56
EPS (TTM)2.4
Dividend & YieldN/A (N/A)
1 Month Average Volume749,665

News & Press Releases

Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow
Blood products company Haemonetics (NYSEHAE). will be announcing earnings results tomorrow before the bell. Here’s what to expect.
Via StockStory · February 5, 2025
How Is The Market Feeling About Haemonetics?benzinga.com
Via Benzinga · January 31, 2025
While growth is established for NYSE:HAE, the stock's valuation remains reasonable.chartmill.com
For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSEHAE) is worth considering.
Via Chartmill · December 13, 2024
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga.com
Via Benzinga · December 6, 2024
The Latest Analyst Ratings For Haemoneticsbenzinga.com
Via Benzinga · December 4, 2024
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.chartmill.com
In the world of growth stocks, NYSE:HAE shines as a value proposition.
Via Chartmill · November 21, 2024
Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings)benzinga.com
Via Benzinga · November 8, 2024
NYSE:HAE is not too expensive for the growth it is showing.chartmill.com
While growth is established for NYSE:HAE, the stock's valuation remains reasonable.
Via Chartmill · October 31, 2024
Despite its growth, NYSE:HAE remains within the realm of affordability.chartmill.com
HAEMONETICS CORP/MASS (NYSEHAE), a growth stock which is not overvalued.
Via Chartmill · October 10, 2024
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases.
By Aligos Therapeutics · Via GlobeNewswire · September 24, 2024
NYSE:HAE stands out as a growth opportunity that won't break the bank.chartmill.com
Investors should take note ofHAEMONETICS CORP/MASS (NYSEHAE), a growth stock that remains attractively priced.
Via Chartmill · September 18, 2024
What Analysts Are Saying About Haemonetics Stockbenzinga.com
Via Benzinga · September 10, 2024
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.chartmill.com
Looking for growth without the hefty price tag? Consider NYSE:HAE.
Via Chartmill · August 28, 2024
Analyst Expectations For Haemonetics's Futurebenzinga.com
Via Benzinga · August 22, 2024
NYSE:HAE stands out as a growth opportunity that won't break the bank.chartmill.com
NYSE:HAE is not too expensive for the growth it is showing.
Via Chartmill · July 16, 2024
Looking for growth without the hefty price tag? Consider NYSE:HAE.chartmill.com
HAEMONETICS CORP/MASS (NYSEHAE) stands out as a growth opportunity that won't break the bank.
Via Chartmill · June 25, 2024
NYSE:HAE, a growth stock which is not overvalued.chartmill.com
Despite its growth, HAEMONETICS CORP/MASS (NYSEHAE) remains within the realm of affordability.
Via Chartmill · June 3, 2024
Top 3 Health Care Stocks That Are Set To Fly This Quarterbenzinga.com
Via Benzinga · August 16, 2024
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.chartmill.com
Investors seeking growth at a reasonable cost should explore HAEMONETICS CORP/MASS (NYSEHAE).
Via Chartmill · August 6, 2024
Sotera Health Appoints Christopher Simon to the Board of Directors
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors.
By Sotera Health Services, LLC · Via GlobeNewswire · August 1, 2024
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analystbenzinga.com
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112.
Via Benzinga · June 12, 2024
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesdaybenzinga.com
Via Benzinga · June 12, 2024
4 Analysts Assess Haemonetics: What You Need To Knowbenzinga.com
Via Benzinga · May 10, 2024
These 3 Companies Boast Bright Outlookstalkmarkets.com
Favorable earnings estimate revisions are key for a stock to move higher. Let’s examine a few highly ranked stocks, including Stride, Interactive Brokers, and Haemonetics.
Via Talk Markets · June 5, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · May 21, 2024